- Home
- BIAF vs AEI Comparison
BIAF vs AEI Comparison
Compare BIAF & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- AEI
- Stock Information
- Founded
- BIAF 2014
- AEI 2014
- Country
- BIAF United States
- AEI United States
- Employees
- BIAF N/A
- AEI N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AEI Building operators
- Sector
- BIAF Health Care
- AEI Real Estate
- Exchange
- BIAF Nasdaq
- AEI Nasdaq
- Market Cap
- BIAF 12.2M
- AEI 10.9M
- IPO Year
- BIAF 2022
- AEI N/A
- Fundamental
- Price
- BIAF $0.35
- AEI $1.52
- Analyst Decision
- BIAF Hold
- AEI
- Analyst Count
- BIAF 1
- AEI 0
- Target Price
- BIAF N/A
- AEI N/A
- AVG Volume (30 Days)
- BIAF 12.3M
- AEI 163.5K
- Earning Date
- BIAF 08-13-2025
- AEI 08-12-2025
- Dividend Yield
- BIAF N/A
- AEI N/A
- EPS Growth
- BIAF N/A
- AEI N/A
- EPS
- BIAF N/A
- AEI N/A
- Revenue
- BIAF $8,809,228.00
- AEI $16,097,995.00
- Revenue This Year
- BIAF N/A
- AEI N/A
- Revenue Next Year
- BIAF $20.00
- AEI N/A
- P/E Ratio
- BIAF N/A
- AEI N/A
- Revenue Growth
- BIAF 78.40
- AEI N/A
- 52 Week Low
- BIAF $0.16
- AEI $0.70
- 52 Week High
- BIAF $2.99
- AEI $2.61
- Technical
- Relative Strength Index (RSI)
- BIAF 56.35
- AEI 71.77
- Support Level
- BIAF $0.27
- AEI $1.17
- Resistance Level
- BIAF $0.38
- AEI $1.38
- Average True Range (ATR)
- BIAF 0.04
- AEI 0.12
- MACD
- BIAF 0.01
- AEI 0.03
- Stochastic Oscillator
- BIAF 73.43
- AEI 83.05
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.